25 results
PRE 14A
QNCX
Quince Therapeutics Inc
4 Apr 23
Preliminary proxy
4:33pm
Officer are held by the same person, our board of directors will designate a Lead Independent Director. We established a Lead Independent Director role … without management, which provides the board of directors with the benefit of having the perspective of independent directors. The Lead Independent Director presides
8-K
EX-3.2
pbp9qwmethpq5g12t1
1 Aug 22
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
9:17am
424B5
40587gp68eq8m
19 May 22
Prospectus supplement for primary offering
4:44pm
POS AM
z9yk fe6d25i14h
4 Mar 22
Prospectus update (post-effective amendment)
4:04pm
POSASR
ivfot3
7 Feb 22
Automatic shelf registration (post-effective amendment)
5:01pm
424B5
z61l54yiu0b31q kdy
23 Dec 21
Prospectus supplement for primary offering
5:24pm
S-3ASR
lu5so
1 Jun 20
Automatic shelf registration
4:46pm
DEF 14A
nk0tdmplix
22 Apr 20
Definitive proxy
3:26pm
10-K
6tnueiuv
16 Mar 20
Annual report
4:16pm
10-K
EX-4.3
4d396
16 Mar 20
Annual report
4:16pm
8-K
EX-3.1
h1skt4i9g
13 May 19
Cortexyme, Inc. Announces Pricing of Initial Public Offering
5:01pm
8-K
EX-3.2
4ez3n6nkd7x0mplc16
13 May 19
Cortexyme, Inc. Announces Pricing of Initial Public Offering
5:01pm
424B4
yemw 2eeibvw
9 May 19
Prospectus supplement with pricing info
5:14pm